Triad of trichomegaly, alopecia and male-pattern hair growth during treatment with erlotinib in non-small-cell lung cancer.
BACKGROUND
Description of the cutaneous side effects of erlotinib.


METHODS
Report with images of a single case.


METHODS
Case report and review of the literature.


CONCLUSIONS
Erlotinib is associated with significant cutaneous toxicity which should be recognised and managed appropriately.
Forde
P
P
Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland. pforde1980@hotmail.com
Murphy
C
C
O'Sullivan
C
C
Carney
D
D
D000230:Adenocarcinoma / Q000188:drug therapy*; D000505:Alopecia / Q000139:chemically induced*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D005140:Eyelashes / Q000187:drug effects; D005260:Female; D006801:Humans; D006983:Hypertrichosis / Q000139:chemically induced*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use*
D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors